Dr. Cortes Discusses TKI Cessation in CML

Jorge E. Cortes, MD
Published: Friday, Mar 02, 2018



Jorge E. Cortes, MD, professor and deputy chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the success of tyrosine kinase inhibitor (TKI) cessation in patients with chronic myeloid leukemia (CML).

Of the patients who start treatment with a second-generation TKI, 40% become eligible for treatment discontinuation over time, says Cortes. Of those patients who become eligible, 50% will be able to remain off therapy when their physician stops treatment.

According to Cortes, only 20% of total patients can successfully have treatment discontinuation. These results are very good, Cortes adds, as there was a time when this was thought to not be possible. However, there is still room for improvement.
 
SELECTED
LANGUAGE


Jorge E. Cortes, MD, professor and deputy chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the success of tyrosine kinase inhibitor (TKI) cessation in patients with chronic myeloid leukemia (CML).

Of the patients who start treatment with a second-generation TKI, 40% become eligible for treatment discontinuation over time, says Cortes. Of those patients who become eligible, 50% will be able to remain off therapy when their physician stops treatment.

According to Cortes, only 20% of total patients can successfully have treatment discontinuation. These results are very good, Cortes adds, as there was a time when this was thought to not be possible. However, there is still room for improvement.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x